Sanofi (NASDAQ:SNY) Shares Sold by Meitav Investment House Ltd.

Meitav Investment House Ltd. lessened its stake in Sanofi (NASDAQ:SNY - Free Report) by 83.2% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 17,500 shares of the company's stock after selling 86,857 shares during the quarter. Meitav Investment House Ltd.'s holdings in Sanofi were worth $870,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of SNY. Clearbridge Investments LLC raised its holdings in Sanofi by 8.4% in the 3rd quarter. Clearbridge Investments LLC now owns 184,630 shares of the company's stock worth $9,904,000 after purchasing an additional 14,362 shares during the period. Dynamic Advisor Solutions LLC acquired a new position in Sanofi in the 4th quarter worth about $2,104,000. Soros Fund Management LLC acquired a new position in Sanofi in the 3rd quarter worth about $11,533,000. Clear Street Markets LLC raised its holdings in Sanofi by 352.8% in the 3rd quarter. Clear Street Markets LLC now owns 130,183 shares of the company's stock worth $6,983,000 after purchasing an additional 101,430 shares during the period. Finally, BKM Wealth Management LLC acquired a new position in Sanofi in the 4th quarter worth about $237,000. Institutional investors and hedge funds own 10.04% of the company's stock.

Sanofi Price Performance

Shares of Sanofi stock traded down $0.67 during mid-day trading on Friday, reaching $45.93. 1,693,869 shares of the stock traded hands, compared to its average volume of 1,843,650. The company has a quick ratio of 0.87, a current ratio of 1.27 and a debt-to-equity ratio of 0.19. The business has a 50-day moving average of $47.60 and a 200 day moving average of $48.88. The stock has a market capitalization of $116.18 billion, a PE ratio of 19.46, a PEG ratio of 1.75 and a beta of 0.61. Sanofi has a fifty-two week low of $42.63 and a fifty-two week high of $57.82.

Sanofi (NASDAQ:SNY - Get Free Report) last posted its quarterly earnings results on Thursday, February 1st. The company reported $0.89 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.94 by ($0.05). The company had revenue of $11.76 billion during the quarter, compared to analysts' expectations of $13.02 billion. Sanofi had a net margin of 12.56% and a return on equity of 27.47%. On average, analysts predict that Sanofi will post 4.19 EPS for the current year.

Sanofi Increases Dividend

The business also recently declared an annual dividend, which will be paid on Thursday, June 6th. Stockholders of record on Friday, May 10th will be given a $1.478 dividend. The ex-dividend date of this dividend is Thursday, May 9th. This is a positive change from Sanofi's previous annual dividend of $1.38. This represents a dividend yield of 2.98%. Sanofi's dividend payout ratio is 58.47%.

Analysts Set New Price Targets

A number of research firms recently weighed in on SNY. StockNews.com cut Sanofi from a "strong-buy" rating to a "buy" rating in a report on Tuesday, February 27th. TheStreet cut Sanofi from a "b" rating to a "c" rating in a report on Friday, February 9th. Finally, Morgan Stanley initiated coverage on Sanofi in a report on Tuesday, January 23rd. They set an "equal weight" rating and a $55.00 target price for the company. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and three have issued a buy rating to the company's stock. According to MarketBeat, Sanofi has an average rating of "Hold" and an average target price of $55.00.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.